The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

Phase I

9771: Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination with Cisplatin in Patients with Refractory Solid Tumors. National Cancer Institute Developmental Therapeutics Clinic; Chen, A. P. (301) 496-4291

9898: A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor. City of Hope Comprehensive Cancer Center LAO; Riess, Jonathan W. (916) 734-3772

9903: A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor. Dana-Farber - Harvard Cancer Center LAO; Oxnard, Geoffrey Raymond. (617) 632-6049

Phase II

ALTE1621: Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial. Children’s Oncology Group; Armenian, Saro H. (626) 471-7320

EA3132: Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN). ECOG-ACRIN Cancer Research Group; Ferris, Robert Louis. (412) 623-1416

S1500: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET). SWOG; Pal, Sumanta Kumar. (626) 256-4673

Other Phases

AAML15B7-Q: Comparison of Molecular Features of Pediatric CML and Adult CML. Children’s Oncology Group; Sakamoto, Kathleen Miho. (650) 725-9250

AAML15B8-Q: Chimeric Antigen Receptor T Cell Immunotherapy for Acute Myeloid Leukemia. Children’s Oncology Group; Aplenc, Richard. (267) 426-7252

AAML15B9-Q: Nox4 Inhibition as a Therapeutic Target in FLT3/ITD+ AML. Children’s Oncology Group; Metts, Jonathan Layne. (404) 727-3246

AAML16B1-Q: Identification and Development of Biomarker Profiles to Predict Clinical Outcomes for Acute Myeloid Leukemia (AML) Patients with NPM1pos/FLT3-ITDneg Genotype. Children’s Oncology Group; Stirewalt, Derek Lynn. (206) 667-5386

AEWS15B2-Q: Prognostic Significance of STAG2 Loss and TP53 Mutations in Ewing Sarcoma. Children’s Oncology Group; Crompton, Brian. (617) 632-4468

NHLBI-MDS: The National Myelodysplastic Syndromes (MDS) Study. ECOG-ACRIN Cancer Research Group; Sekeres, Mikkael Aaron. (216) 445-9353